Prelude Therapeutics Inc (PRLD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $275.32M
Last updated: Nov 17, 2026 at 11:05 AM ET
Prelude Therapeutics Inc (PRLD) Financials: Revenue, Profit and Cash Flow
Prelude Therapeutics reported revenue of $12.14M for the fiscal year ended Dec 31, 2025, up 73.4% from the year before. That year, net income was -$99.50M with a net margin of -819.6%, operating cash flow was -$56.30M and free cash flow was -$56.37M. The quarter ended Sep 30, 2026 had revenue of $5.65M and net income of -$12.54M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $12.14M | +73.4% | 100.0% | -861.3% | -819.6% |
| Dec 2024 | $7.00M | N/A | 100.0% | -1995.9% | -1816.8% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.14M | $7.00M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $149.00K |
| Gross profit | $12.14M | $7.00M | $0 | $0 | $0 | $0 | $0 | -$149.00K |
| Research and development | $94.30M | $118.00M | $103.39M | $92.89M | $86.78M | $48.18M | $24.28M | $12.62M |
| Operating income | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.73M | -$58.76M | -$28.11M | -$14.97M |
| Net income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | -$14.68M |
| EBITDA | -$98.16M | -$130.04M | N/A | -$111.52M | -$109.42M | -$56.39M | -$27.19M | -$14.83M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65M | $5.70M | $4.58M | $5.64M | $6.50M | $0 | $0 | $4.00M | $3.00M | $0 | $0 | $3.42M |
| Gross profit | $5.65M | $5.70M | $4.58M | $5.64M | $6.50M | $0 | $0 | $4.00M | $3.00M | $0 | $0 | -$331.00K |
| Operating income | -$14.27M | -$15.45M | -$14.18M | -$17.35M | -$20.42M | -$32.19M | -$34.61M | -$33.83M | -$34.38M | -$37.16M | -$34.34M | -$37.38M |
| Net income | -$12.54M | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | -$32.09M | -$28.73M | -$32.27M | -$34.74M | -$31.43M | -$33.08M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $2.74M by $32.51M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $141.31M | $175.51M | $277.67M | $220.50M | $305.10M | $223.59M | $21.87M | $16.41M |
| Current assets | $105.69M | $135.90M | $235.59M | $204.38M | $295.12M | $220.81M | $20.22M | $15.60M |
| Cash and equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M | $218.31M | $18.88M | $15.60M |
| Total liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.20M | $11.41M | $4.84M | $39.10M |
| Short-term debt | $2.74M | $2.70M | $1.48M | $1.83M | $1.74M | N/A | $258.00K | N/A |
| Shareholder equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.90M | $212.18M | -$49.41M | -$22.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $175.49M | $189.36M | $119.64M | $141.31M | $94.75M | $114.92M | $141.26M | $175.51M | $197.22M | $224.29M | $247.11M | $277.67M |
| Total liabilities | $51.35M | $55.63M | $59.46M | $72.68M | $36.22M | $39.08M | $38.08M | $44.06M | $40.79M | $42.02M | $36.37M | $40.58M |
| Cash and equivalents | $23.41M | $26.33M | $21.76M | $35.26M | $47.53M | $25.75M | $40.27M | $12.47M | $11.13M | $27.83M | $24.71M | $25.29M |
| Shareholder equity | $124.14M | $133.73M | $60.18M | $68.64M | $58.53M | $75.84M | $103.18M | $131.46M | $156.43M | $182.28M | $210.73M | $237.09M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$56.30M | -$102.89M | -$107.06M | -$83.73M | -$83.53M | -$46.18M | -$25.66M | -$12.95M |
| Capital expenditures | $67.00K | $764.00K | $3.51M | $3.02M | $2.32M | $621.00K | $780.00K | $529.00K |
| Free cash flow | -$56.37M | -$103.65M | -$110.58M | -$86.75M | -$85.85M | -$46.80M | -$26.45M | -$13.48M |
| Share repurchases | $0 | $110.00K | $2.80M | N/A | $303.00K | $12.00K | $0 | N/A |
| Investing cash flow | $53.46M | $90.19M | -$34.65M | $81.69M | -$263.80M | -$621.00K | -$780.00K | -$529.00K |
| Financing cash flow | $24.82M | -$120.00K | $136.40M | $815.00K | $164.90M | $246.23M | $29.73M | $17.94M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.78M | -$15.57M | -$21.68M | $23.12M | -$19.11M | -$26.07M | -$34.23M | -$20.74M | -$27.30M | -$23.06M | -$31.79M | -$23.58M |
| Capital expenditures | $35.00K | N/A | $0 | $0 | $0 | $20.00K | $47.00K | $53.00K | $63.00K | $359.00K | $289.00K | $1.13M |
| Free cash flow | -$13.81M | N/A | -$21.68M | $23.12M | -$19.11M | -$26.09M | -$34.28M | -$20.80M | -$27.36M | -$23.42M | -$32.08M | -$24.71M |
Frequently Asked Questions About PRLD
What is Prelude Therapeutics' annual revenue?
Prelude Therapeutics reported revenue of $12.14M for the fiscal year ended Dec 31, 2025.
How fast is Prelude Therapeutics' revenue growing?
Revenue was up 73.4% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Prelude Therapeutics profitable?
No. Prelude Therapeutics reported net income of -$99.50M for the fiscal year ended Dec 31, 2025, with a net margin of -819.6%.
How much free cash flow does PRLD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$56.30M minus capital expenditures of $67.00K produced free cash flow of -$56.37M.
How much debt does Prelude Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $2.74M and cash and equivalents of $35.26M.
PRLD pages: Overview, Earnings, Forecast, Financials, Competitors